- $914.60m
- $533.92m
Solid Biosciences Q1 net loss widens on higher R&D costs
Solid Biosciences Q4 net loss widens on higher R&D costs
NASDAQ RESUMED AT 01:58 PM
Brief: Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial
NASDAQ TRADE HALT HALT NEWS PENDING AT 12:55 PM
Uniqure jumps after FDA vaccines chief Vinay Prasad to step down
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences
Solid Biosciences to raise $240 mln in private funding, shares rise
Brief: Solid Biosciences Announces Oversubscribed $240 Million Private Placement
Brief: Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy
Brief: Solid Biosciences Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy
Brief: Solid Biosciences Doses First Participant In First-In-Class Phase 1B Falcon Trial Evaluating Sgt-212 Dual-Route Gene Therapy For The Treatment Of Friedreich’S Ataxia
Brief: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Solid Biosciences To Showcase Proprietary Next-Generation Capsid AAV-SLB101 And Cardiac Gene Therapy Pipeline At The 22nd Global Cardiovascular Clinical Trialists Forum
Brief: Solid Biosciences Receives FDA Rare Pediatric Disease Designation For Sgt-212 Dual Route Of Administration Gene Therapy
Brief: Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences For The Use Of Proprietary Next-Generation Capsid Aav-Slb101
Solid Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary